An interventional study of Cohesive bandage fixation of pulse oximeter probe and Standard adhesive fixation of pulse oximeter probe in Skin Injury, Premature Birth and Medical Adhesive Related Skin Injury, sponsored by Uskudar University. Not yet recruiting at 1 site in Turkey (Türkiye). Open to participants aged 0 Years to 28 Days. Per ClinicalTrials.gov, last updated 2026-10-07.
Sponsored by Uskudar University · Not applicable, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 247 studies in Premature Birth with a site in Turkey — 44 open to participants now, 49 under way, none of them phase 3. Premature Birth · Turkey.
Among the 247 studies in Premature Birth with a site in Turkey, this one is the 95th largest by planned enrollment of the 197 interventional ones that give a count, is one of 19 that started in 2026, is one of 192 with no phase, reaches primary completion later than 39 of the 48 other live ones, and was the 244th registered.
2,557 studies on the registry are indexed under Premature Birth; 504 are open to participants now.
Browse Premature Birth studies →44 of the 247 studies in Premature Birth with a site in Turkey are open now. Recruiting first, the newest first:
Mersin University · Sites in Turkey
Ages 32 wk–37 mo
Kubra Nur Kabakcı Sarıdağ · Sites in Turkey
Ages 32 wk–37 wk · Healthy volunteers
Gazi University · Sites in Turkey
Ages 3 mo–12 mo
Ataturk University · Sites in Turkey
Ages 28 wk–32 wk · Healthy volunteers
Uludag University · Sites in Turkey
Ages 0 hrs–6 hrs
A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →
Of the 318 Premature Birth studies recruiting now, 88 (28%) set no upper age limit and 226 (71%) stop at 75 or younger; 243 take children under 18; 104 take healthy volunteers.
This study: 0 Years to 28 Days · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
247 studies; the count open now beside each. This study's row is marked.
First in 2009; this study’s year is marked. 19 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 64 is below the median of 84 across 1,670 interventional studies indexed under Premature Birth.
Median enrollment 64 across the 197 interventional studies, 90 across the 49 observational. Of the 169 that completed or were terminated, 1 (1%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 247 has an industry lead sponsor. The 10 most frequent:
Uskudar University is the lead sponsor of 173 studies on the registry; 38 are open to participants now.
Uskudar University has 1 study filed under Premature Birth — fewer than ten, so there is no comparison to draw.
9 of the studies in Premature Birth with a site in Turkey that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07864298Uskudar UniversityCohesive Bandage Fixation of Pulse Oximeter Probes and Skin Condition in Preterm Neonates | 2026-11 |
| NCT07525167Konya City HospitalEarly Prediction of Bronchopulmonary Dysplasia in Preterm Infants Using Clinical Data | 2026-12-01 |
| NCT06823115Indiana UniversityAssessment of Worldwide Acute Kidney Injury Epidemiology in Neonates 2.0 | 2027-01 |
| NCT07917871Marmara UniversityEffects of Environmental Comfort and Oral Motor Stimulation on Comfort and Oral Feeding Readiness in Preterm Infants | 2027-01-01 |
| NCT07350018Uludag UniversityCalfactant vs Poractant Alfa Using a Less Invasive Technique in Preterm Infants With Respiratory Distress Syndrome | 2027-02-20 |
Add all 9 to your calendar (.ics) → With an account.
Among the 247 studies in Premature Birth with a site in Turkey, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Pulse oximeter probes are used to continuously monitor oxygen levels in newborn babies in intensive care. These probes are usually attached to the baby's hand or foot with adhesive tape and must be moved to a new site every few hours. Repeatedly sticking and removing adhesive can damage the delicate skin of premature babies.
The investigators have developed a new way to secure the probe without any adhesive touching the skin: the probe's adhesive side is attached to a soft, self-adhering (cohesive) bandage that wraps around the baby's hand or foot. The bandage sticks only to itself, not to the skin.
The purpose of this study is to find out whether securing the probe with a cohesive bandage protects the skin better than the standard method of taping the probe directly to the skin. Sixty-four premature babies (born at 32 to 36 weeks) will be randomly placed in one of two groups. In both groups, the probe will be placed on each hand and foot for four hours in turn, for a total of 16 hours. The skin under the probe will be photographed and scored by two nurses who do not know which method was used.
Background: The skin of preterm neonates has an immature stratum corneum and a weak dermal-epidermal junction, which makes it vulnerable to epidermal stripping when medical adhesives are removed. The pulse oximeter probe is one of the most frequently applied and repositioned adhesive devices in the neonatal intensive care unit. Probe-related skin injuries, including adhesive-related and pressure-related damage and burns, have been reported. Existing preventive approaches (barrier films, silicone tapes, hydrocolloid dressings) reduce but do not eliminate adhesive contact with the skin. No published randomized controlled trial has tested a fixation method specific to pulse oximeter probes.
Intervention: In the experimental group, a piece of latex-free cohesive bandage (5 cm wide, length 1.5 times the circumference of the application site) is prepared. Two openings matching the probe's light-emitting diode and photodetector windows are cut into the bandage. The probe's original adhesive surface is attached to the bandage, and the free ends of the bandage are wrapped around the extremity so that they adhere only to each other. Alignment of the emitter and detector is verified. Wrap tension is standardized with a capillary refill test (refill within 2 seconds after 5 seconds of pressure proximal to the probe) and the absence of visible skin indentation. In the control group, the probe is applied directly to the skin according to routine practice and manufacturer instructions; the same capillary refill check is performed.
Exposure schedule: In both groups, the probe is rotated across four sites (right foot, left foot, right hand, left hand) at four-hour intervals. Each site carries the probe only once, for a total exposure of 16 hours per infant. A safety check (capillary refill, skin redness, probe displacement) is performed at the second hour of each application.
Outcome assessment: All four sites are photographed before any probe application (baseline). Each site is photographed again 30 minutes after probe removal under standardized conditions (fixed 20 cm distance, ring LED lighting, locked white balance, scale and color reference card in frame). Images are coded, presented in random order, and scored independently by two observers blinded to group allocation using the Neonatal Skin Condition Score adapted to the probe site.
Randomization: A computer-generated block randomization list with variable block sizes (4 and 6) is prepared by an independent statistician. Allocations are concealed in sequentially numbered, opaque, sealed envelopes.
Pilot phase: Before the main study, 8 to 10 neonates will be included in a pilot phase to test the adapted scoring form, photography setup and interobserver agreement, and to compare oxygen saturation readings between cohesive bandage and standard adhesive fixation (Bland-Altman analysis). Pilot data will not be included in the main analysis.
Statistical analysis: The unit of analysis is the application site. Because the four sites of each infant are not independent, a linear mixed-effects model will be used, with infant as a random effect and group, baseline score and site (hand/foot) as fixed effects. Analysis will follow the intention-to-treat principle, with a per-protocol sensitivity analysis.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The pulse oximeter probe is attached to a cohesive bandage wrapped around the extremity, with no adhesive contact with the skin. The probe is rotated across four extremities at four-hour intervals (16 hours in total).
Other: Cohesive bandage fixation of pulse oximeter probe
The pulse oximeter probe is applied directly to the skin with its own adhesive according to routine practice and manufacturer instructions. The probe is rotated across four extremities at four-hour intervals (16 hours in total).
Other: Standard adhesive fixation of pulse oximeter probe
The adhesive surface of the pulse oximeter probe is attached to a latex-free cohesive bandage (5 cm wide, length 1.5 times the circumference of the site) with openings matching the emitter and detector windows. The bandage ends adhere only to each other, so no adhesive contacts the skin. Wrap tension is checked with a capillary refill test.
The pulse oximeter probe is applied directly to the skin with its original adhesive according to routine practice and manufacturer instructions.
Neonatal Skin Condition Score (NSCS) total score at the probe application site
Skin condition at each probe application site is assessed with the Neonatal Skin Condition Score adapted to the probe site. The score includes three items (dryness, erythema, skin breakdown), each scored from 1 to 3; the total score ranges from 3 (best) to 9 (worst). Scoring is performed on standardized photographs by two independent observers blinded to group allocation, and the mean of the two observers' scores is used.
Time frame: 30 minutes after probe removal at the end of each 4-hour application (up to 16 hours)
Plan to share: No — Individual participant data will not be shared due to the small sample size of neonatal participants and the need to protect patient confidentiality, including standardized skin photographs. Aggregated results will be reported in publications.
No publications or documents are linked to this record.
Start is estimated for Oct 2026; primary completion for Nov 2026, 1 month later.
Of 746 non-industry interventional studies with no phase under Premature Birth, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 47. This study's planned 1 month is below that.
Counting every sponsor, half of 764 studies reached it within 24 months; a quarter within 12 and three quarters within 47.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.